Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Madrigal Pharmaceuticals (YDO1) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
ResmetiromHeart Failure With Preserved Ejection Fraction (Hfpef), Mash - Metabolic Dysfunction-Associated SteatohepatitisPhase IRecruitingResmetirom in Patients With MASH and HFpEFAug 25, 2026―
Resmetirom, Rezdiffra, Actos/Pioglitazone, Farxiga/DapagliflozinMash - Metabolic Dysfunction-Associated SteatohepatitisPhase IVRecruitingRezdiffra® With Concomitant Therapies Commonly Used to Treat Comorbidities in Adults With MASH and F2-F3 FibrosisAug 25, 2026―
ResmetiromMash, Mash - Metabolic Dysfunction-Associated SteatohepatitisPhase IIRecruitingStudy of Resmetirom in Children and Adolescents With MASHAug 10, 2026
ResmetiromMash - Metabolic Dysfunction-Associated SteatohepatitisPhase IIRecruitingStudy to Evaluate Resmetirom in Post-Liver Transplant Patients With MASHJan 07, 2026
100 Mg Resmetirom TabletRenal ImpairmentPhase ICompletedA Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal FunctionApr 30, 2024―
ResmetiromNash, Cirrhosis, LiverPhase IIIActive Not RecruitingA Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)Aug 11, 2022―
ResmetiromNon-Alcoholic Fatty Liver DiseasePhase IIIActive Not RecruitingA Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)Jun 18, 2021―
Mgl-3196, Liver Biopsy, ResmetiromNash - Nonalcoholic SteatohepatitisPhase IIIActive Not RecruitingA Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and FibrosisMar 26, 2019―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Madrigal (DE:YDO1) have in its pipeline
Madrigal Pharmaceuticals DE:YDO1 is currently developing the following drugs: Resmetirom, Resmetirom, Rezdiffra, Actos/Pioglitazone, Farxiga/Dapagliflozin, 100 Mg Resmetirom Tablet, Mgl-3196, Liver Biopsy, Resmetirom. These drug candidates are in various stages of clinical development as the company works toward FDA approval.